Andrew Reardon
CLO & Secretary · 4 filings · Latest: Jun 1, 2026
LIGAND PHARMACEUTICALS INC
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
LGND | Andrew Reardon | CLO & Secretary | Jun 1, 2026 | Sale | $227.06 | 5,000 | $1.1M | 41,382 | |
LGND | Andrew Reardon | CLO & Secretary | Jun 1, 2026 | Option Exercise | $52.27 | 5,000 | $261.4K | 46,382 | |
LGND | Andrew Reardon | CLO & Secretary | May 1, 2026 | Sale | $231.31 | 5,000 | $1.2M | 41,382 | |
LGND | Andrew Reardon | CLO & Secretary | May 1, 2026 | Option Exercise | $52.27 | 5,000 | $261.4K | 46,382 | |
LGND | Andrew Reardon | CLO & Secretary | Apr 1, 2026 | Sale | $201.24 | 5,000 | $1.0M | 41,382 | |
LGND | Andrew Reardon | CLO & Secretary | Apr 1, 2026 | Option Exercise | $52.27 | 5,000 | $261.4K | 46,382 | |
LGND | Andrew Reardon | CLO & Secretary | Mar 2, 2026 | Grant/Award | $0.00 | 4,513 | — | 41,382 |